유승근 (유전자종합연구소, 삼성서울병원)님 | 한빛사연구자 > 한빛사

유전자종합연구소, 삼성서울병원

CV File

최종업데이트 2026.03.18.

[Letter to the Editor] Utility of the neutrophil-to-lymphocyte ratio extends to patients from East Asia
- J. Clin. Invest., Mar 16 2026, 136 (6) e202712 | https://doi.org/10.1172/JCI202712
- 2026-03
- 의약학
- 한빛사논문
A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer
- Cancer Discov., Feb 27 2026, | https://doi.org/10.1158/2159-8290.CD-25-1774
- 2026-02
- 의약학
- 한빛사논문
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
- Nat. Med., Jan 06 2025, | https://doi.org/10.1038/s41591-024-03398-5
- 2025-01
- 의약학
- 한빛사논문
A whole-genome reference panel of 14,393 individuals for East Asian populations accelerates discovery of rare functional variants
- Sci. Adv., Volume 9, Issue 32 Aug 2023 | https://doi.org/10.1126/sciadv.adg6319
- 2023-08
- 의약학
- 한빛사논문
- 유승근(서울대학교, Icahn School of Medicine at Mount Sinai)
Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers
- PLoS Genet., Published: August 5, 2016 | https://doi.org/10.1371/journal.pgen.1006239
- 2016-08
- 의약학
- 상위피인용논문
- 유승근(Memorial Sloan Kettering Cancer Center)
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
- Nat. Biotechnol., Published: 01 November 2021 | https://doi.org/10.1038/s41587-021-01070-8
- 2021-11
- 의약학
- 한빛사논문
NARD: whole-genome reference panel of 1779 Northeast Asians improves imputation accuracy of rare and low-frequency variants
- Genome Med., Published: 22 October 2019 | https://doi.org/10.1186/s13073-019-0677-z
- 2019-11
- 의약학
- 한빛사논문
Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer
- Nat. Commun., Published 24 June 2019, 10, Article number: 2764 | https://doi.org/10.1038/s41467-019-10680-5
- 2019-06
- 의약학
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기